(NASDAQ: QTTB) Q32 Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Q32 Bio's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast QTTB's revenue for 2028 to be $648,913,118, with the lowest QTTB revenue forecast at $648,913,118, and the highest QTTB revenue forecast at $648,913,118. On average, 1 Wall Street analysts forecast QTTB's revenue for 2029 to be $1,897,948,894, with the lowest QTTB revenue forecast at $1,897,948,894, and the highest QTTB revenue forecast at $1,897,948,894.
In 2030, QTTB is forecast to generate $2,766,419,082 in revenue, with the lowest revenue forecast at $2,766,419,082 and the highest revenue forecast at $2,766,419,082.